Target intelligence / Profile preview

RNA, U2 small nuclear 1 (RNU2-1)

Target
RNU2-1
Molecular classification
Small nuclear RNA (snRNA), Spliceosomal non-coding RNA, Other (not a protein, not a receptor, not an enzyme)
01

Overview

RNA, U2 small nuclear 1 (RNU2-1), commonly referred to as U2 or U2 snRNA, encodes a highly conserved small nuclear RNA that is an essential component of the major spliceosome in eukaryotic organisms[4][1]. U2 snRNA, assembled into U2 small nuclear ribonucleoprotein (snRNP), is responsible for recognizing the branch point sequence in introns and participates in the catalysis of pre-mRNA splicing by forming base pairs with U6 snRNA and interacting with protein complexes SF3a and SF3b[4][7][3]. This process is fundamental to the maturation of messenger RNA and the regulation of gene expression. U2 snRNAs exhibit extensive post-transcriptional modifications, including pseudouridylation and 2’-O-methylation[4]. Its loci are associated with specialized nuclear domains (coiled bodies), indicating a spatial organization of snRNA transcription and processing[5]. Disease relevance is primarily through recurrent mutations that have been observed in certain tumor types, but it is not considered a classical therapeutic target such as a receptor, enzyme, or transporter[2][1][4].

Other names
U2RNU2U2 snRNAU2 spliceosomal RNA
02

Mechanism of action

Not applicable; U2 snRNA is not directly drug-targeted.

03

Biological functions

Pre-mRNA splicingIntron recognition (branch point sequence recognition)RNA–protein and RNA–RNA mediation within the spliceosomeRegulation of eukaryotic gene expression
04

Disease associations

Cancer (somatic mutations linked to B cell-derived tumors, prostate and pancreatic cancers)Other (no major role in classic disease pathways like inflammation or infection, mainly disease association via mutations)
05

Safety considerations

Not directly relevant, as there are no drugs targeting U2 snRNA; however, mutations in the gene may have oncogenic implications
06

Interacting drugs

None known; there are no approved drugs targeting U2 snRNA directly.
07

Biomarkers

Mutations (e.g., n.28C>T in RNU2-1) may serve as molecular biomarkers in certain cancers

Beyond the preview

Go deeper on RNA, U2 small nuclear 1 (RNU2-1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, U2 small nuclear 1 (RNU2-1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call